Comparison of three immunological tests for leprosy diagnosis and detection of subclinical infection

Leprosy Review

Volumn 82, Issue 4, 2011, Pages 389-401

  Lobato, Janaina ^a   Costa, Mariana Pena ^a   Reis, Érica de Melo ^a   Gonçalves, Maria Aparecida ^a   Spencer, John S ^b   Brennan, Patrick J ^b   Goulart, Luiz Ricardo ^a,c   Goulart, Isabela Maria Bernardes ^a  

^a Instituto de Gené tica e Bioquímica   (Brazil)

^b Department of Environmental and Radiological Health Sciences   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DISACCHARIDE; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN M ANTIBODY; LEPROMIN; LEPROSTATIC AGENT; NATURAL DISACCHARIDE O LINKED TO HUMAN SERUM ALBUMIN; PHENOLIC GLYCOLIPID I ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; ASYMPTOMATIC INFECTION; BACTERIAL INDEX; BACTERIAL LOAD; BORDERLINE BORDERLINE LEPROSY; BORDERLINE LEPROSY; BORDERLINE TUBERCULOID LEPROSY; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HOUSEHOLD; HUMAN; IMMUNOAFFINITY CHROMATOGRAPHY; IMMUNOASSAY; INTERMETHOD COMPARISON; LATERAL FLOW TEST; LEPROMATOUS LEPROSY; LEPROSY; MAJOR CLINICAL STUDY; MULTIBACILLARY LEPROSY; PAUCIBACILLARY LEPROSY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; TUBERCULOID LEPROSY;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; ASYMPTOMATIC INFECTIONS; BRAZIL; GLYCOLIPIDS; HUMANS; IMMUNOLOGIC TESTS; LEPROSY; MYCOBACTERIUM LEPRAE;

EID: 84855887518     PISSN: 03057518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. World Health Organization. Weekly Epidemiological Record. 2010; 85: 337-348.
2. World Health Organization. Global Strategy for Further Reducing the Leprosy Burden and Sustaining Leprosy Control Activities (Plan period: 2006-2010) 2005; 53: 1-17.
3. Ridley DS, Jopling WH. Classification of leprosy according to immunity: a five group system. Int J Leprosy, 1966; 34: 255-273.
4. World Health Organization. Study Group Chemotherapy of leprosy. Technical Report Series 1994; 847. Geneva, Switzerland.
5. Croft RP, Smith WC, Nicholls P, Richardus JH. Sensitivity and specificity of methods of classification of leprosy without use of skin-smear examination. Int J Lepr, 1998; 66: 445-450.
6. Cho S, Cellona RV, Villahermosa LG et al. Detection of phenolic glycolipid i of Mycobacterium leprae in sera from leprosy patients before and after start of multidrug therapy. Clin Diagn Lab Immun, 2001; 8: 138-142.
7. Chanteau S, Cartel JL, Celerier P et al. PGL-I antigen and antibody detection in leprosy patients: evolution under chemotherapy. Int J Lepr, 1989; 57: 735-743.
8. Tomimori-Yamashita J, Nguyen TH, Maeda SM et al. Anti-phenolic Glycolipid-I (PGL-I) determination using blood collection on filter paper in leprosy patients. Rev Inst Med Trop, 1999; 41: 239-242.
9. Shuring RP, Moet FJ, Pahan D et al. Association between anti-PGL-I IgM and clinical and demographic parameters in leprosy. Lepr Rev, 2006; 77: 343-355.
10. Maeda SM, Rotta O, Michalany NS et al. Comparison between anti-PGL-I serology and Mitsuda reaction: clinical reading, microscopic findings and immunohistochemical analysis. Lepr Rev, 2003; 74: 263-274.
11. de Souza FC, Marcos EV, Ura S et al. Comparative study between the Mitsuda test and the human leukocyte antigens in leprosy patients. Rev Soc Bras Med Trop, 2007; 40: 188-191.
12. Chatterjee D, Cho SN, Brennan PJ, Aspinall GO. Chemical synthesis and seroreactivity of O-(3,6-di-O-methylbeta-D-glucopyranosyl)-(1----4)-O-(2,3-di-O-methyl-alpha-L-rhamnopyranosyl)-(1----9)-oxynonanoylbovine serum albumin-the leprosy-specific, natural dissacaridase-octyl-neoglycoprotein. Carbohyd Res, 1986; 156: 39-56.
13. Hussain R, Jamil S, Kifayet A et al. Quantitation of IgM antibodies to the M. leprae synthetic disaccharide can predict early bacterial multiplication in leprosy. Int J Leprosy, 1990; 58: 491-502.
14. Barros RPC, Oliveira MLWR. Detection of specific antibodies for the phenolic-1 glycolipid antigen of M. leprae (antiPGL-1IgM): applications and limitations. An Bras Dermatol, 2000; 75: 745-753.
15. Bührer-Sékula S, Smits HL, Gussenhoven GC et al. Simple and Fast Lateral Flow Test for classification of leprosy patients and identification of contacts with high risk of developing leprosy. J Clin Microbiol, 2003; 41: 1991-1995.
16. Bührer-Sékula S, Visschedijk J, Grossi MAF et al. The ML Flow test as a point of care test for leprosy control programmes: potential effects on classification of leprosy patients. Lepr Rev, 2007; 78: 70-79.
17. Parkash O, Kumar A, Pandey R et al. Performance of a lateral flow test for the detection of leprosy patients in India. J Med Microbiol, 2008; 57: 130-132.
18. Contin LA, Alves CJ, Fogagnolo L et al. Use of the ML-Flow test as a tool in classifying and treating leprosy. An Bras Dermatol, 2011; 86: 91-95.
19. Douglas JT, Worth RM. Field evaluation of an ELISA to detect antibody in leprosy patients and their contacts. Int J Lepr, 1984; 57: 744-751.
20. Douglas JT, Cellona RV, Fajardo TT, Jr et al. Prospective study of serological conversion as a risk factor for development of leprosy among household contacts. Clin Diagn Lab Immun, 2004; 11: 897-900.
21. Lobato J, Silva DA, Mineo TW et al. Detection of immunoglobulin G antibodies to Neospora caninum in humans: high seropositivity rates in patients who are infected by human immunodeficiency virus or have neurological disorders. Clin Vaccine Immunol, 2006; 13: 84-89.
22. rd ed., CIBA-GEIGY, Basle, 1990; pp. 63.
23. Gaylord H, Brennan PJ. Leprosy and the leprosy bacillus: recent developments in characterization of antigens and immunology of the disease. Annu Rev Microbiol, 1987; 41: 645-675.
24. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics, 1977; 33: 159-174.
25. Noordeen SK. The epidemiology of leprosy. In: Hastings RC (ed). Leprosy: Medicine in the tropics. Churchill Livingstone, New York, 1985; pp. 15-30.
26. Van Beers SM, Izumi S, Madrid B et al. An Epidemiological study of leprosy infection by serology and polymerase chain reaction. Int J Lepr, 1994; 62: 1-9.
27. Van Beers SM, Hatta M, Klatser PR. Patient contact is the major determinant in incident leprosy: implications for future control. Int J Lepr, 1999; 67: 119-128.
28. Van Beers S, Hatta M, Klatser PR. Seroprevalence rates of antibodies to phenolic glycolipid-1 among school children as an indicator of leprosy endemicity. Int J Lepr, 1999; 67: 243-249.
29. Wallace C, Clayton D, Fine P. Estimating the relative risk ratio for leprosy in Karonga District, Malawi. Lepr Rev, 2003; 74: 133-140.
30. Brennan PJ, Barrow WW. Evidence for species lipid antigens in Mycobacterium leprae. Int J Lepr, 1980; 48: 382-387.
31. Hunter SW, Brennan PJ. A novel glycolipid from M. leprae possibly involved in immunogenecity and pathogenicity. J Bacteriol, 1981; 147: 728-735.
32. Fujiwara T, Hunter SW, Cho S et al. Chemical synthesis and serology of disaccharides and trisaccharides of phenolic glycolipid antigens from the leprosy bacillus and preparation of a disaccharide protein conjugate for serodiagnosis of leprosy. Infect Immun, 1984; 43: 245-252.
33. Lyon S, Lyon AC, Da Silva RC et al. A comparison of ML Flow serology and slit skin smears to assess the bacterial load in newly diagnosed leprosy patients in Brazil. Lepr Rev, 2008; 79: 162-170.
34. Lyon S, Castorina da Silva R, Lyon AC et al. Association of the ML Flow serologic test to slit skin smear. Rev Soc Bras Med Trop, 2008; 41: 23-26.
35. Bührer-Sékula S, Illarramendi X, Teles RB et al. The additional benefit of the ML Flow test to classify leprosy patients. Acta Trop, 2009; 111: 172-176.
36. Bührer-Sékula S, Visschedijk J, Grossi MA et al. The ML flow test as a point of care test for leprosy control programmes: potential effects on classification of leprosy patients. Lepr Rev, 2007; 78: 70-79.
37. Fujiwara T, Aspinall GO, Hunter SW, Brennan PJ. Chemical Synthesis of the trisaccharide unit of species-specific a phenolic glycolipid from Mycobacterium leprae. Carbohyd Res, 1987; 163: 41-52.
38. Da Silva RC, Lyon S, Lyon AC et al. Correlation between ELISA and ML Flow assays applied to 60 Brazilian patients affected by leprosy. Trans R Soc Trop Med Hyg, 2010; 104: 546-550.
39. Chanteau S, Cartel JL, Roux J et al. Comparison of synthetic antigens for detecting antibodies to phenolic glycolipid I in patients with leprosy and their household contacts. J Infect Dis, 1988; 157: 770-776.
40. Cho SN, Fujiwara T, Hunter SW et al. Use of an artificial antigen containing the 3,6-di-O-methylbeta-D-glucopyranosyl epitope for the serodiagnosis of Leprosy. J Infect Dis, 1984; 150: 311-322.
41. Fujiwara T, Hunter SW, Brennan PJ. Chemical Synthesis of the disaccharides of the specific phenolic glycolipid antigens from Mycobacterium leprae and of related sugars. Carbohyd Res, 1986; 148: 287-298.
42. Bach MA, Wallach D, Flaguel B. Antibodies to Phenolic glycolipid-I and to whole M. leprae, in leprosy patients: evolution during therapy. Int J Lepr, 1986; 54: 256-267.
43. Roche PW, Britton WJ, Failbus SS et al. Serological monitoring of the response to chemotherapy in leprosy patients. Int J Lepr, 1993; 61: 35-43.
44. Silva EA, Iyer A, Ura S et al. Utility of measuring serum levels of anti-PGL-I antibody, neopterin and C-reactive protein in monitoring leprosy patients during multidrug treatment and reactions. Trop Med Int Health, 2007; 12: 1450-1458.
45. Ebenezer GJ, Job A, Abraham S et al. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study. Int J Lepr, 1999; 67: 292-297.
46. Job CK, Jayakumar J, Kearney M, Gillis TP. Transmission of leprosy: a study of skin and nasal secretions of household contacts of leprosy patients using PCR. Am J Trop Med Hyg, 2008; 78: 518-521.
47. Fine PE, Floyd S, Stanford JL et al. Environmental mycobacteria in northern Malawi: implications for the epidemiology of tuberculosis and leprosy. Epidemiol Infect, 2001; 126: 379-387.
48. Shetty VP, Suchitra K, Uplekar MW, Antia NH. Persistence of Mycobacterium leprae in the peripheral nerve as compared to the skin of multidrug treated leprosy patients. Lepr Rev, 1992; 63: 329-336.
49. Cunaman jr A, Chan GP, Douglas JT. Risk of development of leprosy among Culion contacts. Int J Lepr, 1998; 66: 578.
50. Bakker MI, Hatta M, Kwenang A et al. Risk factors for developing leprosy: a population-based cohort study in Indonesia. Lepr Rev, 2006; 77: 48-61.
51. Goulart LR, Goulart IM. Leprosy: diagnostic and control challenges for a worldwide disease. Arch Dermatol Res, 2008; 300: 269-290.
52. Martinez TS, Figueira MM, Costa AV et al. Oral mucosa as a source of Mycobacterium leprae infection and transmission, and implications of bacterial DNA detection and the immunological status. Clin Microbiol Infect, 2010; doi: 101111/j.1469-0691.2010.03453.x.
53. Goulart IM, Bernardes Souza DO, Marques CR et al. Risk and protective factors for leprosy development determined by epidemiological surveillance of household contacts. Clin Vaccine Immunol, 2008; 15: 101-105.
54. Cho SN, Yanagibara DL, Hunter SW et al. Serological specificity of phenolic glycolipid in from Mycobacterium leprae and use in serodiagnosis of leprosy. Infect Immun, 1983; 41: 1077-1083.
55. Cho SN, Cellona RV, Fajardo TT et al. Detection of phenolic glycolipid-I antigen and antibody in sera from new and relapsed lepromatous patients treated with various drug regimens. Int J Lepr, 1991; 59: 25-31.
56. Cardona-Castro N, Beltràn-Alzate JC, Manrique-Hernàndez R. Survey to identify Mycobacterium leprae-infected household contacts of patients from prevalent regions of leprosy in Colombia. Mem Inst Oswaldo Cruz., 2008; 103: 332-336.
57. Duthie MS, Hay MN, Rada EM et al. Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers. Eur J Clin Microbiol Infect Dis, 2011; May 5, DOI: 10.1007/s10096-011-1221-2.
58. Agis F, Schlich P, Cartel JL, Guidi C, Bach MA. Use of anti-M. leprae phenolic glycolipid-I antibody detection for early diagnosis and prognosis of leprosy. Int J Leprosy, 1988; 56: 527-535.
59. Saad MA, Medeiros MA, Gallo ME et al. IgM immunoglobulins reacting with the phenolic glycolipid-1 antigen from Mycobacterium leprae in sera of leprosy patients and their contacts. Mem Inst Oswaldo Cruz, 1990; 85: 191-194.
60. Moura RS, Calado KL, Oliveira MLW, Bührer-Sékula S. Leprosy serology using PGL-1: a systematic review. Rev Soc Bras Med Trop, 2008; 41: 11-18.
61. ILA. Summary of the Report of the ILA Technical Forum. Lepr Rev, 2002; 70: 3-5.